September 15, 2026

CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th

VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) --**CytoDyn Inc. (OTCQB: CYDY)** ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E. Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17th, 2026.

DATE: Thursday, September 17, 2026

TIME: 12:30 PM PT / 3:30 PM ET

REGISTER HERE

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event atwww.virtualinvestorconferences.com.

About CytoDyn

CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients' quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer

companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

CONTACTS:

CytoDyn Corporate
ir@cytodyn.com

CytoDyn Media
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com

Virtual Investor Conferences
Greg Young
VP Corporate Services, Investor Access
OTC Markets Group
(212) 652-5958
greg@otcmarkets.com

Source: Virtual Investor Conferences